Alvotech efnir til útboðs á hlutabréfum í Bandaríkjunum að andvirði 125 milljóna Bandaríkjadala eða ríflega fimmtán og hálfum milljarði íslenskra króna.
Félagið tilkynnti um þetta í kvöld. Það hefur jafnframt veitt umsjónaraðilum útboðsins heimild til þess að kaupa til viðbótar allt að 15 prósent bréfanna sem bjóðast á útboðsgenginu.
Samhliða opna útboðinu segir í tilkynningunni að Alvotech geri ráð fyrir að gera áskriftarsamninga við tiltekna fjárfesta sem eru fagfjárfestar eða viðurkenndir gagnaðilar á Evrópska efnahagssvæðinu. Þeim fjárfestum verða boðin bréf á sama gengi og í almenna útboðinu.
„Alvotech hyggst nýta afrakstur af sölu hlutabréfanna til þess að fjármagna þróun nýrra hliðstæðna líftæknilyfja, í veltufé og til að standa straum af rekstrarkostnaði, þar á meðal til þess að vernda lyfjahugvit félagsins, almennra rekstrarútgjalda, fjárfestinga í fastafjármunum, kaupa á búnaði, í samstarfsverkefnum, forklínískum og klínískum rannsóknum, við vöruþróun, undirbúning markaðssetningar nýrra lyfja og til endurgreiðslu skulda eða endurfjármögnunar,“ segir í tilkynningunni.
Sameiginlegir umsjónaraðilar almenna útboðsins eru fjárfestingarbankarnir BofA Securities, Jefferies og Evercore ISI.
Read the full article at Vísir →📄Source document: Alvotech announcement→4 reports
RÚV FréttirState / PublicCenter3 days agoAlvotech, an Icelandic biotechnology company based in the United States, completed a stock offering worth 20.6 billion Icelandic kronas. Investors purchased approximately 26 million shares at a price of $3.75 per share. Additionally, European investors signed agreements to purchase roughly 18 million shares at the same price.
Bias read (Center): The article provides factual information about a financial transaction involving an Icelandic company without any apparent ideological framing, bias, or emphasis on political aspects. The content focuses purely on economic activity and does not involve political controversy or opinionated language.
VísirIndependentCenter3 days agoAlvotech, an Icelandic biotechnology company, raised approximately 20.6 billion Icelandic kronas through a share offering in the United States and subscription agreements with European investors. The offering included shares sold at $3.75 per share, with underwriters such as BofA Securities, Jefferies, and Evercore ISI participating. The total proceeds from the U.S. offering amounted to $98 million, equivalent to around 12.2 billion kronas. Additionally, Alvotech secured subscription agreements worth $67 million, equivalent to 8.4 billion kronas, from European investors. The company plans to使用
Bias read (Center): The article provides factual information about a financial transaction involving an Icelandic biotechnology company without taking a stance or using biased language.
RÚV FréttirState / PublicCenter5 days ago Alvotech chemicals to supply stocks to the equivalent of 15.6 billion crownsAlvotech has announced an upcoming stock offering in the United States following a recent closed offering in the European Economic Area. The value of the shares to be purchased by investors is estimated at around 15.6 billion Icelandic kronas or 125 million US dollars. The underwriters for the public offering include financial institutions such as BofA Securities, Jefferies, and Evercore ISI. According to the announcement from Alvotech, the company has granted underwriters the option to purchase up to 15% of the shares offered in the public offering, excluding discounts and commissions, within
Bias read (Center): The article provides factual information about a corporate stock offering without any apparent ideological framing, loaded language, or biased sourcing. It focuses on business operations and financial details without taking a stance on political issues.
Official sources cited
- organisation Alvotech Announcement
VísirIndependentCenter5 days ago Substances for the supply of securities worth $125 millionAlvotech has announced an offering of shares valued at $125 million (approximately 1.5 billion Icelandic kronas) in the United States. The company also granted existing shareholders the option to purchase up to an additional 15% of the shares offered. The announcement states that Alvotech plans to use proceeds from the sale of shares to fund the development of new biopharmaceutical products, cover operational costs, protect intellectual property, invest in real estate, acquire equipment, conduct collaborative projects, clinical trials, product development, market preparation for new drugs, and
Bias read (Center): The article reports on a financial transaction by Alvotech without taking a stance or using biased language. It provides factual information about the share offering and its intended uses.
IS